HI
PLX icon

Harbour Investments’s Protalix BioTherapeutics PLX Stock Holding History

Harbour Investments’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Hold
6,000
– – ﹤0.01% 3163
2026
Q1 		$13K Buy
+6,000
New +$14.9K ﹤0.01% 3124
2021
Q4 		– Sell
-3,000
Closed -$4K – 3421
2021
Q3 		$4K Buy
+3,000
New +$4.56K ﹤0.01% 3090

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Harbour Investments's PLX Position: Q2 2026 in Review

Harbour Investments held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 6,000 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3163.

Harbour Investments first reported a position in PLX in Q3 2021 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Harbour Investments held 6,000 shares of Protalix BioTherapeutics worth $14K as of Q2 2026.
  • Harbour Investments left its Protalix BioTherapeutics share count unchanged in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3163 holding.
  • Harbour Investments first reported a position in Protalix BioTherapeutics in Q3 2021 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.